Galmed announces a delay in the initiation of its primary sclerosing cholangitis (psc) phase 2a study

Tel aviv, israel , nov. 20, 2023 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its primary sclerosing cholangitis (psc) ph 2a study.
GLMD Ratings Summary
GLMD Quant Ranking